Industrializing Individualized Medicines
EveryONE Medicines is creating a scalable path to individualized medicines—so everyone who can benefit from today’s technologies can access treatments where they need them, when they need them.
Millions of children suffer from severe genetic diseases that are individually defined by their mutations. While we can now identify these mutations and design medicines to target the root cause, the healthcare system is still built around a population model — one medicine for one large disease — and it does not work for the individual.
EveryONE Medicines is building a new approach
We are developing standardized, scalable pathways to design, deliver, and gain approval for individualized medicines — enabling thousands of medicines for small patient populations to be developed through the same end-to-end process.
The time is now
Regulatory and payer barriers are lowering, with the FDA and MHRA advancing process-based pathways with the expectation of reimbursement. What were once one-off, heroic efforts can now become a scalable model of care.
EveryONE Medicines is built on:
- The first individualized medicine (milasen) as proof of concept
- Dozens of patients treated through individualized genetic therapies
- Emerging FDA and MHRA process-approval pathways
- A master protocol designed to enable individualized medicines at scale
